This is a textbook post-earnings cashless exercise cluster — CFO and CMO sold only to cover option exercise costs and taxes. No discretionary bearish signal. The 56% historical win rate on AVTX reports and the +4.89% avg T+20 return suggest the market has been rewarding pipeline catalysts, not punishing insider sales. Monitor for any unexercised option overhang, but this filing is noise. The cross-filing amplifiers (cluster-earnings-context + cluster-insider-trades) are not triggered here because the sales are non-discretionary.
Price Chart
Executive Summary
CFO Christopher Ryan and CMO Mittie executed derivative exercises and sold shares totaling ~$819K in open-market sales over a 7-day window, following the Q2 2026 earnings release 14 days prior. The sales are 100% same-day cashless exercises of stock options — the shares were sold to cover exercise costs and taxes, not a directional bearish bet. At a $1.1B market cap, the $819K represents ~0.07% of market cap, well below the 0.1% materiality threshold for insider sales. The cluster is routine post-earnings option exercise activity, not an informed sell signal.
Key Financial Metrics
Key Facts
- CFO Sullivan Christopher Ryan exercised 72,852 options at $9.88 strike and sold 72,725 shares at ~$19.85-$20.05, netting ~$1.45M in proceeds but surrendering shares to cover exercise costs
- CMO Doyle Mittie exercised 1,000 options at $12.65 and sold 1,000 shares at $20.00, netting ~$7,350
- Total open-market sales: ~$819K, representing ~0.07% of $1.1B market cap — trivial
- All sales were same-day cashless exercises (Code M exercise + Code S sale), consistent with tax-withholding and exercise-cost coverage, not discretionary bearish positioning
- Cluster occurred 14 days after Q2 2026 earnings (net loss $36.4M, cash $472.2M) — within standard post-earnings blackout window opening
Financial Impact
~$819K in open-market sales, 0.07% of market cap — immaterial
Risk Factors
- CFO sold ~72,725 shares in total — if future exercises continue at this pace, insider ownership could decline meaningfully over time
- Pre-revenue biotech with no approved products; pipeline execution risk remains the primary driver regardless of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-AVTX-1787198524842 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access